Advanced

CD11b+ and sca-1+ cells exert the main beneficial effects of systemically administered bone marrow-derivedmononuclear cells in a murinemodel of mixed Th2/Th17 allergic airway inflammation

Cruz, Fernanda F.; Borg, Zachary D.; Goodwin, Meagan; Coffey, Amy L.; Wagner, Darcy E. LU ; Rocco, Patricia R. M. and Weiss, Daniel J. (2016) In Stem cells translational medicine 5(4). p.488-499
Abstract

Systemic administration of bone marrow-derived mononuclear cells (BMDMCs) or bone marrowderivedmesenchymal stromal cells (MSCs) reduces inflammation and airway hyperresponsiveness (AHR) in amurinemodel of Th2-mediated eosinophilic allergic airway inflammation. However, since BMDMCs are a heterogeneous population that includesMSCs, it is unclearwhether theMSCs alone are responsible for the BMDMC effects. To determine which BMDMC population(s) is responsible for ameliorating AHR and lung inflammation in a model of mixed Th2-eosinophilic and Th17-neutrophilic allergic airway inflammation, reminiscent of severe clinical asthma, BMDMCs obtained from normal C57Bl/6 mice were serially depleted of CD45, CD34, CD11b, CD3, CD19, CD31, or Sca-1... (More)

Systemic administration of bone marrow-derived mononuclear cells (BMDMCs) or bone marrowderivedmesenchymal stromal cells (MSCs) reduces inflammation and airway hyperresponsiveness (AHR) in amurinemodel of Th2-mediated eosinophilic allergic airway inflammation. However, since BMDMCs are a heterogeneous population that includesMSCs, it is unclearwhether theMSCs alone are responsible for the BMDMC effects. To determine which BMDMC population(s) is responsible for ameliorating AHR and lung inflammation in a model of mixed Th2-eosinophilic and Th17-neutrophilic allergic airway inflammation, reminiscent of severe clinical asthma, BMDMCs obtained from normal C57Bl/6 mice were serially depleted of CD45, CD34, CD11b, CD3, CD19, CD31, or Sca-1 positive cells. The different resulting cell populations were then assessed for ability to reduce lung inflammation and AHR in mixed Th2/Th17 allergic airway inflammation induced by mucosal sensitization to and challenge with Aspergillus hyphal extract (AHE) in syngeneic C56Bl/6 mice. BMDMCs depleted of either CD11b-positive (CD11b+) or Sca-1-positive (Sca-1+) cells were unable to ameliorate AHR or lung inflammation in this model. Depletion of the other cell types did not diminish the ameliorating effects of BMDMC administration. In conclusion, in the current model of allergic inflammation, CD11b+ cells (monocytes, macrophages, dendritic cells) and Sca-1+ cells (MSCs) are responsible for the beneficial effects of BMDMCs.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
keywords
Asthma, Bone marrow-derived mononuclear cells, Inflammation, Mesenchymal stromal cells, Monocyte, Mouse
in
Stem cells translational medicine
volume
5
issue
4
pages
488 - 499
publisher
AlphaMed Press
external identifiers
  • scopus:84961262919
ISSN
2157-6564
DOI
10.5966/sctm.2015-0141
language
English
LU publication?
no
id
759493c4-718b-4e90-9a0a-345cc2c86a7a
date added to LUP
2017-08-15 14:36:25
date last changed
2017-08-22 16:17:00
@article{759493c4-718b-4e90-9a0a-345cc2c86a7a,
  abstract     = {<p>Systemic administration of bone marrow-derived mononuclear cells (BMDMCs) or bone marrowderivedmesenchymal stromal cells (MSCs) reduces inflammation and airway hyperresponsiveness (AHR) in amurinemodel of Th2-mediated eosinophilic allergic airway inflammation. However, since BMDMCs are a heterogeneous population that includesMSCs, it is unclearwhether theMSCs alone are responsible for the BMDMC effects. To determine which BMDMC population(s) is responsible for ameliorating AHR and lung inflammation in a model of mixed Th2-eosinophilic and Th17-neutrophilic allergic airway inflammation, reminiscent of severe clinical asthma, BMDMCs obtained from normal C57Bl/6 mice were serially depleted of CD45, CD34, CD11b, CD3, CD19, CD31, or Sca-1 positive cells. The different resulting cell populations were then assessed for ability to reduce lung inflammation and AHR in mixed Th2/Th17 allergic airway inflammation induced by mucosal sensitization to and challenge with Aspergillus hyphal extract (AHE) in syngeneic C56Bl/6 mice. BMDMCs depleted of either CD11b-positive (CD11b+) or Sca-1-positive (Sca-1+) cells were unable to ameliorate AHR or lung inflammation in this model. Depletion of the other cell types did not diminish the ameliorating effects of BMDMC administration. In conclusion, in the current model of allergic inflammation, CD11b+ cells (monocytes, macrophages, dendritic cells) and Sca-1+ cells (MSCs) are responsible for the beneficial effects of BMDMCs.</p>},
  author       = {Cruz, Fernanda F. and Borg, Zachary D. and Goodwin, Meagan and Coffey, Amy L. and Wagner, Darcy E. and Rocco, Patricia R. M. and Weiss, Daniel J.},
  issn         = {2157-6564},
  keyword      = {Asthma,Bone marrow-derived mononuclear cells,Inflammation,Mesenchymal stromal cells,Monocyte,Mouse},
  language     = {eng},
  number       = {4},
  pages        = {488--499},
  publisher    = {AlphaMed Press},
  series       = {Stem cells translational medicine},
  title        = {CD11b+ and sca-1+ cells exert the main beneficial effects of systemically administered bone marrow-derivedmononuclear cells in a murinemodel of mixed Th2/Th17 allergic airway inflammation},
  url          = {http://dx.doi.org/10.5966/sctm.2015-0141},
  volume       = {5},
  year         = {2016},
}